Results 181 to 190 of about 108,133 (341)

Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis

Diabetes, obesity and metabolism, 2017
Zin Z. Htike, F. Zaccardi, D. Papamargaritis, D. Webb, K. Khunti, M. Davies   +5 more
semanticscholar   +1 more source

Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.

The Lancet Gastroenterology and Hepatology, 2023
G. Targher, A. Mantovani, C. Byrne
semanticscholar   +1 more source

Glucagon-like peptide-1 receptors agonists (GLP1 RA).

JPMA. The Journal of the Pakistan Medical Association, 2014
The glucagon-like peptide-1 receptors agonists (GLP1RA) are a relatively new class of drugs, used for management of type 2 diabetes. This review studies the characteristics of these drugs, focusing upon their mechanism of action, intra-class differences, and utility in clinical practice.
openaire   +1 more source

An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller, Linoy Gabay, Oren Barak, Alena Kirzhner, Haitham Abu Khadija, Gabriel Chodick, Edi Vaisbuch, Yael Barer   +7 more
wiley   +1 more source

Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists. [PDF]

OTO Open
Sciscent BY, Eberly HW, Lorenz FJ, Goldrich D, Goyal N, Goldenberg D.   +5 more
europepmc   +1 more source

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review

The Lancet Gastroenterology and Hepatology, 2022
A. Mantovani, C. Byrne, G. Targher
semanticscholar   +1 more source

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay, Dayana El Chaar, Melanie Paquette, Michael Vallis, Diana Sherifali, Paul Oh, Susan Marzolini, Kaberi Dasgupta, Gillian Booth, Mike Lean, Hertzel C. Gerstein, Jordi Salas‐Salvadó, Jacqueline L. Beaudry, Christopher P. F. Marinangeli, Russell J. de Souza, Lawrence A. Leiter, Cyril W. C. Kendall, David J. A. Jenkins, John L. Sievenpiper, Laura Chiavaroli   +19 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis. [PDF]

Cureus
Nashwan AJ.
europepmc   +1 more source

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Circulation, 2017
M. Nauck, J. Meier, M. Cavender, Mirna Abd El Aziz, D. Drucker   +4 more
semanticscholar   +1 more source

Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost‐effectiveness modelling study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Coronary artery calcium (CAC) scoring is observed to improve risk stratification for major adverse cardiovascular events (MACE). Semaglutide, a recently introduced anti‐obesity drug, is very effective, but wider use is limited due to high costs.
Sai Rahul Ponnana, Tong Zhang, Santosh Kumar Sirasapalli, Zhuo Chen, Jean‐Eudes Dazard, Niketh Surya, Shamsa Elhussain, Kanimozhi Sivanantham, Robert Okyere, Ian J. Neeland, Sanjay Rajagopalan, Salil V. Deo   +11 more
wiley   +1 more source